DARE vs CODA vs TPVG vs MNDO

For growth investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger pick with 36. 6% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 9x trailing P/E (6. 2x forward), making it the more compelling value choice. Analysts rate Coda Octopus Group, Inc. (CODA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TriplePoint Venture Growth BDC Corp.

(TPVG) is the cheapest at 4. 9x versus Coda Octopus Group, Inc. at 32. 2x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 6. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Coda Octopus Group, Inc. wins at 5. 33x versus TriplePoint Venture Growth BDC Corp. 's 6. 14x.

Over the past 5 years, Coda Octopus Group, Inc.

(CODA) delivered a total return of +49. 7%, compared to -82. 4% for Daré Bioscience, Inc. (DARE). Over 10 years, the gap is even starker: CODA returned +861. 1% versus DARE's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MIND C.

T. I. Ltd (MNDO) is the lower-risk stock at 0. 05β versus Coda Octopus Group, Inc. 's 0. 99β — meaning CODA is approximately 1829% more volatile than MNDO relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TriplePoint Venture Growth BDC Corp.

(TPVG) is pulling ahead at 36. 6% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: Daré Bioscience, Inc. grew EPS 88. 4% year-over-year, compared to -43. 5% for MIND C. T. I. Ltd. Over a 3-year CAGR, CODA leads at 6. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — TPVG leads at 83. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Coda Octopus Group, Inc. (CODA) is the more undervalued stock at a PEG of 5. 33x versus TriplePoint Venture Growth BDC Corp. 's 6. 14x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, TriplePoint Venture Growth BDC Corp. (TPVG) trades at 6. 2x forward P/E versus 22. 8x for Coda Octopus Group, Inc. — 16. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TPVG: 49. 4% to $8. 95.

In this comparison, MNDO (21.

6% yield), TPVG (17. 1% yield) pay a dividend. DARE, CODA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, MIND C.

T. I. Ltd (MNDO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), 21. 6% yield). Both have compounded well over 10 years (MNDO: +65. 7%, DARE: -99. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DARE (Healthcare) and CODA (Industrials) and TPVG (Financial Services) and MNDO (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DARE is a small-cap quality compounder stock; CODA is a small-cap high-growth stock; TPVG is a small-cap high-growth stock; MNDO is a small-cap deep-value stock. TPVG, MNDO pay a dividend while DARE, CODA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.